Michala de Linde Henriksen^1,2*, Caitlin Bradley², Kim R Love³, Krista Banks², Michael R Lappin² and Stephanie McGrath²

¹Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, USA
²Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, USA
³KR Love Quantitative Consulting and Collaboration, Athens, GA, USA

*Corresponding Author: Michala de Linde Henriksen; Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, USA.

Received: June 03, 2025; Published: July 21, 2025

Abstract

Objective: Cannabidiol (CBD) is thought to have an anti-inflammatory effect. The aim of this pilot study was to investigate the anti inflammatory effect of CBD on diabetic dogs undergoing phacoemulsification. The hypothesis was that dogs treated with CBD would have less short-term and long-term complications from uveitis due to CBDs anti-inflammatory effect.

Methods: This is a pilot study, including dogs with diabetic cataracts. CBD-group = treated with oral CBD 10mg/kg; MCT-group (con trol) = treated with oral medium-chain-triglyceride oil 0.1ml/kg. Both groups were treated PO BID for 28 days starting 7 days pre surgery (Day-1) until 21-days post-surgery (Day-28). A physical examination and complete-blood-count and chemistry panel were performed on Day-1, Day-7 (day of surgery), Day-14, and Day-28. Parameters evaluated for uveitis post-surgery; short-term (flare, post-operative intraocular hypertension [POH]), long-term (glaucoma), as well as visual status (visual versus blind). The follow-up period was 12 months.

Results: CBD-group = 4 dogs (8 eyes), MCT-group = 3 dogs (6 eyes). No uveitis parameters were found to be different between the groups. One eye in each group developed glaucoma; the eye in the CBD-group was blind at the final follow up whereas the eye in the MCT-group was treated for glaucoma and was still visual. A statistically significant difference in alkaline phosphatase (ALP) was found over time for the CBD-group (p < 0.001) but not for the MCT-group (p = 0.317).

Conclusion: Oral CBD did not influence short-term or long-term parameters from uveitis following phacoemulsification in diabetic dogs. ALP was significantly elevated in the CBD-group. This liver enzyme should be monitored in any dogs treated with systemic CBD.

Keywords: Canine; Cataracts; CBD; Diabetes; Uveitis

References

1. Bow Wow Meow pet insurance.
2. Bagley LH and Lavach JD. “Comparison of postoperative phacoemulsification results in dogs with and without diabetes mellitus: 153 cases (1991-1992)”. Journal of the American Veterinary Medical Association 8 (1996): 1165-1169.
3. Davidson MG and Nelms SR. “Chapter 21: Diseases of the lens and cataract formation. In. Veterinary Ophthalmology (eds. Gelatt, Gilger, Kern) fifth edition (2013). Wiley-Blackwell, Ames, Iowa, USA (2013): 1199-1233.
4. Beam S., et al. “A retrospective-cohort study on the development of cataracts in dogs with diabetes mellitus: 200 cases”. Veterinary Ophthalmology 2 (1999): 169-172.
5. Heeley AM., et al. “Diabetes mellitus in dogs attending UK primary-care practice: frequency, risk factors and survival”. Canine Medicine and Genetics 7 (2020): 6.
6. Guptill L., et al. “Time trends and risk factors for diabetes mellitus in dogs: analysis of veterinary medical data base records (1970-1999)”. Veterinary Journal 3 (2003): 240-247.
7. Fracassi F., et al. “Breed distribution of canine diabetes mellitus in Italy”. Veterinary Research Communications 1 (2004): 339-342.
8. Davison LJ., et al. “Study of 253 dogs in the United Kingdom with diabetes mellitus”. Veterinary Record 15 (2005): 467-471.
9. Fall T., et al. “Diabetes mellitus in a population of 180,000 insured dogs: incidence, survival, and breed distribution”. Journal of Veterinary Internal Medicine 6 (2007): 1209-1216.
10. Pascolini D and Mariotti SP. “Global estimates of visual impairment: 2010”. British Journal Ophthalmology5 (2012): 614-618.
11. Wilkie DA and Colitz CMH. “Chapter 22: Surgery of the lens. In. Veterinary Ophthalmology (eds. Gelatt, Gilger, Kern) fifth edition (2013). Wiley-Blackwell, Ames, Iowa, USA (2013): 1234-1286.
12. Uhl LK., et al. “Cataracts and phacoemulsification in the Siberian Husky: A retrospective and multicentric study (2008-2018)”. Veterinary Ophthalmology (2021): 1-13.
13. Monteiro-Steagall BP., et al. “Review: Systemic review of nonsteroidal anti-inflammatory drug induced adverse effects in dogs”. Journal of Veterinary Internal Medicine 27 (2013): 1011-1019.
14. Iffland K and Grotenhermen F. “An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies”. Cannabis Cannabinoid Research1 (2017): 139-154.
15. Henriksen MdL and McGrath S. “Growing interest but limited evidence on the usefulness of cannabidiol in treating ophthalmic disease in dogs: a review”. Journal of the American Veterinary Medical AssociationS2 (2024): S25-S31.
16. Terhaar H., et al. “Pro-inflammatory cytokines in aqueous humor from dogs with anterior uveitis and post-operative ocular hypertension following phacoemulsification, primary glaucoma, and normal healthy eyes”. PLOS ONE (2022): 1-21.
17. Bartner LR., et al. “Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs”. Canadian Journal of Veterinary Research 3 (2018): 178-183.
18. Hendrix D. “Diseases and Surgery of the Canine Anterior Uvea”. In: Gelatt K, Gilger B, Kern T, eds. Veterinary Ophthalmology. 5 ed. Ames, IA: John Wiley and Sons (2013): 1146-1198.
19. Jost HE., et al. “Long-term effect of oral cannabidiol administration to healthy adult dogs on tear production, intraocular pressure, and tear concentration”. Veterinary Ophthalmology 27 (2023): 357-366.
20. Corsato Alvarenga I., et al. “Tolerability of long-term cannabidiol supplementation to healthy adult dogs”. Journal of Veterinary Internal Medicine 38.1 (2023): 326-335.
21. Liu EK., et al. “Anti-inflammatory effects of cannabinoids in endotoxin-induced uveitis”. ARVO Annual Meeting Abstract 46 (2005): 972.
22. Terhaar HM., et al. “The use of shotgun label-free quantitative proteomic mass spectrometry to evaluate the inflammatory response in aqueous humor from horses with uveitis compared to ophthalmologically healthy horses”. Veterinary Ophthalmology 27 (2024): 40-52.
23. Miller S., et al. “Delta9Tetrahydrocannabinol and cannabidiol differentially regulate intraocular pressure”. Investigative Ophthalmology and Visual Science15 (2018): 5904-5911.
24. Foote BC., et al. “Retrospective analysis of ocular neuropathies in diabetic dogs following cataract surgery”. Veterinary Ophthalmology3 (2019): 284-293.
25. Landry MP., et al. “Funduscopic findings following cataract extraction by means of phacoemulsification in diabetic dogs: 52 cases (1993-2003)”. Journal of the American Veterinary Medical Association 225 (2004): 709-716.
26. Weiss L., et al. “Cannabidiol lowers incidence of diabetes in non-obese diabetic mice”. Autoimmunity 2 (2006): 143-151.
27. Lauinger CA and Peacock R. “Marijuana toxicosis in dogs in Melbourne, Australia, following suspected ingestion of human faeces: 15 cases (2011-2020)”. Australian Veterinary Journal 3 (2022): 90-97.

Citation

Citation: Michala de Linde Henriksen., et al. “Anti-Inflammatory Effects of Systemic Cannabidiol in Uveitis Following Phacoemulsification in Dogs: A Pilot Study".Acta Scientific Veterinary Sciences 7.8 (2025): 04-18.

Copyright

Copyright: © 2025 Michala de Linde Henriksen., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.